Results 201 to 210 of about 44,321 (338)

Teclistamab in Elderly Patients With Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis of the French RetrosTECtive Cohort

eJHaem, Volume 7, Issue 1, February 2026.
ABSTRACT Introduction Real‐world data on teclistamab in relapsed or refractory multiple myeloma (R/R MM), particularly in elderly patients, remain limited. Methods We analysed efficacy and safety outcomes in patients ≥ 75 years from the French RetrosTECtive cohort.
A. Coste, S. Godet, S. Manier, J. R. Eveillard, C. Croizier, C. Mariette, C. Breal, H. Manjra, C. Touzeau, M. Mohty, R. Belkhir, A. Bobin, A. Lévêque, B. Cherel, L. Montes, F. Orsini‐Piocelle, L. Frenzel, D. Robu, E. Chalayer, S. Harel, L. Vincent, L. Bauschert, A. Dony, R. Tabrizi, P. Moreau, C. Hulin, A. Perrot   +26 more
wiley   +1 more source

To substitute or not? A systematic review of immunoglobulin replacement therapy in multiple myeloma patients treated with bispecific antibodies. [PDF]

Front Immunol
Paulsen JS, Slørdahl TS.
europepmc   +1 more source

The bispecific antibody targeting VISTA and PD-L1 shows enhanced tumor inhibitory activity in pancreatic, endometrial and breast cancers compared to mono- and combination immune checkpoint blockade [PDF]

Przemysław Bielski, Jan Barczyński, Michał Mikitiuk, Maja Myrcha, Kamil Rykała, Louis Boon, Wiktoria Gąsior, Aleksandra Hec, Tad A. Holak, Tomasz Sitar   +9 more
openalex   +1 more source

Tumor‐Associated Macrophages as Therapeutic Targets: Deciphering Interaction Networks and Advancing Clinical Translation

MedComm, Volume 7, Issue 2, February 2026.
Tumor‐associated macrophages are the most abundant immune cells in the tumor microenvironment, driving malignant progression and treatment resistance. This review summarizes the protumor mechanisms of TAMs (including phagocytosis modulation, metabolic reprogramming, exosomal communication, and immune interactions), evaluates three major strategies ...
Wurihan Bao, Xiaojie Qu, Yiqi Wang, Dan Huang, Huiling Zhang, Mingyuan Dong, Han Sun, Zhaogang Yang, Xuefeng Li   +8 more
wiley   +1 more source

Bispecific antibodies and CAR T cells targeting a TP53 mutation-associated neoantigen show discordant affinity requirements. [PDF]

J Clin Invest
DiNapoli SR, Wright KM, Mog BJ, Pearlman AH, Nichakawade TD, Marcou N, Hsiue EH, Hwang MS, Douglass J, Liu Q, Watson E, Dal Molin M, Cohen JD, Popoli M, Paul S, Konig MF, Wyhs N, Azurmendi PA, Glavaris S, Ge J, Awosika TO, Liu J, Gabrielson KL, Gabelli SB, Pardoll DM, Bettegowda C, Papadopoulos N, Kinzler KW, Zhou S, Vogelstein B.   +29 more
europepmc   +1 more source

Development of a c-MET x CD137 bispecific antibody for targeted immune agonism in cancer immunotherapy

Hong Zhang, Qun Wang, Sireesha Yalavarthi, Lukas Pekar, Steven Shamnoski, Liufang Hu, Laura Helming, Stefan Zielonka, Chunxiao Xu   +8 more
openalex   +1 more source

A detergent-based procedure for the preparation of IgG-like bispecific antibodies in high yield [PDF]

, 2016
Jyoti Gupta, Mehboob Hoque, Masihuz Zaman, Rizwan Hasan Khan, M. Saleemuddin   +4 more
openalex   +1 more source

Advances in Therapeutic Antibody Discovery and Development Targeting G Protein‐Coupled Receptors

Pharmacology Research &Perspectives, Volume 14, Issue 1, February 2026.
ABSTRACT G protein‐coupled receptors (GPCRs) are integral to numerous biological processes and are associated with various diseases across all therapeutic areas. Consequently, GPCRs present substantial potential for antibody‐based therapies. This review offers an overview of the therapeutic GPCR‐antibody target landscape and examines the diversity ...
Catherine J. Hutchings, Serbülent Ünsal, Mathieu Rappas, Matthew Barnes, Maria Waldhoer, Ben Holland, Martin Culka   +6 more
wiley   +1 more source

Integrating MBMA and QSP to Identify Key Covariates and Predict Treatment Outcomes in Relapsed/Refractory Multiple Myeloma

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT This study demonstrates the application of a model based meta analysis (MBMA) framework to characterize the safety and efficacy profiles of therapies in relapsed and refractory multiple myeloma (RRMM). Published clinical trial data were analyzed to evaluate the incidence of Grade ≥ 3 neutropenia and overall response rate (ORR), providing a ...
Zeel Shah, Clifton M. Anderson, Kevin D. McCormick, Celeste Vallejo, William Duncan, Chuanpu Hu, Jian Zhou, Alexander V. Ratushny, Anna G. Kondic   +8 more
wiley   +1 more source

The Landscape of Bispecific Antibodies in Solid Tumor Oncology: Trends, Challenges, and Opportunities. [PDF]

Cancer Med
ElBeblawy R, Jani C, Pérez-Granado J, Gramling M, Desai A.   +4 more
europepmc   +1 more source